An interventional study of Cyanoacrylate Skin Adhesive and Fast Gut Running Epidermal Suture Closure in Surgical Site Infection, Skin Cancer and Wound Healing, sponsored by University of Minnesota. Not yet recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University of Minnesota · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies in Surgical Wound Infection with a site in United States — 31 open to participants now, 34 under way, 4 of them phase 3. Surgical Wound Infection · United States.
Among the 202 studies in Surgical Wound Infection with a site in United States, this one is the 70th largest by planned enrollment of the 177 interventional ones that give a count, is one of 7 that started in 2026, is one of 85 with no phase, reaches primary completion later than 30 of the 33 other live ones, and was the 199th registered.
746 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
Browse Surgical Wound Infection studies →31 of the 202 studies in Surgical Wound Infection with a site in United States are open now. Recruiting first, the newest first:
Montefiore Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Macro Biologics, Inc. · Sites in United States
Ages 18+
Riverside University Health System Medical Center · Sites in United States
Ages 18+ · Women only
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Rhode Island Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Surgical Wound Infection studies recruiting now, 60 (71%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 15 · Phase 3 33 · Phase 4 39
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 200 across 582 interventional studies indexed under Surgical Wound Infection.
Median enrollment 208 across the 177 interventional studies, 300 across the 23 observational. Of the 144 that completed or were terminated, 78 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 202 have an industry lead sponsor. The 10 most frequent:
University of Minnesota is the lead sponsor of 1,217 studies on the registry; 197 are open to participants now.
Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.
University of Minnesota has 4 studies filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
12 of the studies in Surgical Wound Infection with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06014411Hospital for Special Surgery, New YorkEarly Versus Delayed Bathing of Orthopaedic Surgical Wounds | 2026-12 |
| NCT04773457Boston Children's HospitalNeutrophil Phenotypic Profiling and Surgical Site Infections in Surgical Patients | 2026-12-01 |
| NCT04725916Sean DevittStudying How Outpatient Water affEcts Risks With Drains (SHOWER Study) | 2026-12-15 |
| NCT06378359University of MinnesotaEffectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients | 2026-12-31 |
| NCT07379684Macro Biologics, Inc.A Study of Amicidin-β Topical Solution for Patients With a Contaminated or Infected Surgical or Traumatic Wound or Cutaneous Abscess | 2027-02-28 |
Add all 12 to your calendar (.ics) → With an account.
Among the 202 studies in Surgical Wound Infection with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare surgical site infection after linear repair with or without cyanoacrylate skin adhesive following Mohs micrographic surgery or wide local excision.
Adult participants undergoing Mohs micrographic surgery or wide local excision for skin cancer with a surgical defect suitable for linear repair will be stratified by suture type and randomized to standardized running epidermal suture closure with or without cyanoacrylate skin adhesive.
The primary outcome is surgical site infection within 30 days after surgery. Secondary outcomes include scar quality, treatment satisfaction, wound care burden, wound healing characteristics, antibiotic use, culture results, health care utilization related to wound concerns, and adverse events.
Surgical site infection is an uncommon but clinically important complication after dermatologic surgery. Linear repairs are frequently performed after Mohs micrographic surgery and wide local excision, and closure technique may affect infection risk, wound healing, scar quality, and patient experience.
This is a prospective, randomized, stratified parallel group clinical study evaluating postoperative outcomes after standardized running epidermal suture closure with or without cyanoacrylate skin adhesive. Adult patients undergoing Mohs micrographic surgery or wide local excision for skin cancer will be screened on the day of surgery. Participants will be eligible if the surgical defect is suitable for linear repair using standardized running epidermal sutures.
Participants will be stratified by suture type. In the absorbable suture stratum, participants will be randomized using a 2×2 factorial design to fast gut or Vicryl Rapide suture material and to adhesive use or no adhesive. In the non-absorbable suture stratum, participants will receive Prolene and will be randomized to closure with or without cyanoacrylate skin adhesive.
All participants will undergo Mohs micrographic surgery or wide local excision as part of standard clinical care. Research procedures include randomization of closure approach, standardized wound photography, follow-up assessments at approximately 2 weeks and 3 months, documentation of infection or suspected infection, wound healing assessment, adverse event assessment, and patient-reported outcome measures.
The primary outcome is surgical site infection within 30 days following linear repair. Secondary outcomes include antibiotic use, wound healing metrics, patient-reported treatment satisfaction and wound care burden, scar quality using the Patient and Observer Scar Assessment Scale 3.0 Linear Scar Version, culture results and treatment descriptions when infection is suspected, health care utilization related to wound concerns, and adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the absorbable suture stratum will receive standardized running epidermal closure using fast gut sutures followed by cyanoacrylate skin adhesive.
Device: Cyanoacrylate Skin Adhesive · Procedure: Fast Gut Running Epidermal Suture Closure
Participants in the absorbable suture stratum will receive standardized running epidermal closure using fast gut sutures without cyanoacrylate skin adhesive.
Procedure: Fast Gut Running Epidermal Suture Closure
Participants in the absorbable suture stratum will receive standardized running epidermal closure using Vicryl Rapide sutures followed by cyanoacrylate skin adhesive.
Device: Cyanoacrylate Skin Adhesive · Procedure: Vicryl Rapide Running Epidermal Suture Closure
Participants in the absorbable suture stratum will receive standardized running epidermal closure using Vicryl Rapide sutures without cyanoacrylate skin adhesive.
Procedure: Vicryl Rapide Running Epidermal Suture Closure
Participants in the non-absorbable suture stratum will receive standardized running epidermal closure using Prolene sutures followed by cyanoacrylate skin adhesive.
Device: Cyanoacrylate Skin Adhesive · Procedure: Prolene Running Epidermal Suture Closure
Participants in the non-absorbable suture stratum will receive standardized running epidermal closure using Prolene sutures without cyanoacrylate skin adhesive.
Procedure: Prolene Running Epidermal Suture Closure
Cyanoacrylate skin adhesive will be applied in a thin, continuous layer along the repaired wound after hemostasis and epidermal closure are complete. The adhesive is an FDA-approved topical wound closure product used within its labeled indication.
Also known as: 2-Octyl Cyanoacrylate
Standardized running epidermal closure will be performed using fast gut absorbable suture material after Mohs micrographic surgery or wide local excision.
Standardized running epidermal closure will be performed using Vicryl Rapide absorbable suture material after Mohs micrographic surgery or wide local excision.
Standardized running epidermal closure will be performed using Prolene non-absorbable suture material after Mohs micrographic surgery or wide local excision.
Surgical Site Infection Within 30 Days After Linear Repair
Surgical site infection will be assessed within 30 days following linear repair after Mohs micrographic surgery or wide local excision. Surgical site infection is defined as culture-confirmed infection or strong clinical suspicion of infection when a culture cannot be obtained, including purulent discharge, erythema with edema or warmth, drainage consistent with infection, or cellulitis requiring antibiotic therapy.
Time frame: Within 30 days after Mohs micrographic surgery or wide local excision
Systemic Antibiotic Use
Prophylactic and postoperative systemic antibiotic use will be documented, including indication, timing, and duration. This includes antibiotics prescribed for suspected infection at follow-up or interval visits.
Time frame: Baseline through 30 days after surgery
Wound Healing Complications
Wound healing will be assessed by documenting dehiscence, necrosis, delayed epithelialization, and other healing-related complications.
Time frame: 7 to 14 days and 30 days after surgery
Treatment Satisfaction
Treatment satisfaction will be assessed using the Oxford Skin Cancer Treatment Scale.
Time frame: 2 weeks and 3 months after surgery
Wound Care Burden
Wound care burden will be assessed using a brief custom wound-care questionnaire evaluating time spent on wound care, satisfaction with the wound-care regimen, and wound-care preference.
Time frame: 2 weeks after surgery
Scar Quality
Scar quality will be assessed using the Patient and Observer Scar Assessment Scale 3.0 Linear Scar Version. Participants will complete the patient scale, and a trained blinded assessor will complete the observer scale using standardized 3-month wound photographs.
Time frame: 3 months after surgery
Culture Results and Infection Treatment
For wounds with suspected infection, culture organisms, antibiotic selection, treatment course, and subsequent clinical course will be summarized descriptively.
Time frame: Within 30 days after surgery
Health Care Utilization Related to Wound Concerns
Urgent care visits, emergency department evaluations, specialty consultations, or hospitalizations related to postoperative infection or wound complications will be documented.
Time frame: Baseline through 3 months after surgery
Adverse Events
Adverse events will include hematoma, allergic or irritant contact dermatitis related to suture material or cyanoacrylate adhesive, and other unexpected surgical or wound-related adverse events.
Time frame: Baseline through 3 months after surgery
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
Of 201 non-industry interventional studies with no phase under Surgical Wound Infection, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 24 months is close to that.
Counting every sponsor, half of 208 studies reached it within 24 months; a quarter within 12 and three quarters within 45.
Start moved 3 times since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, last on Nov 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.